NCT03652532 is a NA clinical trial of Alternate Day Fasting in Overweight, sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT03652532?

NCT03652532 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT03652532?

Interventions in NCT03652532: Alternate Day Fasting, Exercise.

What condition does NCT03652532 study?

NCT03652532 studies Overweight, Obesity, Diet Modification, Exercise.

Is NCT03652532 still recruiting?

NCT03652532 is currently completed. Last updated 29 August 2018.

Last reviewed 2018-08-29 · How we verify

NCT03652532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alternate Day Fasting and Exercise in Overweight or Obese Adults

Completed NA Last updated 29 August 2018

What this trial tests

NA trial testing Alternate Day Fasting in Overweight in 100 participants. Completed in 8 March 2016.

Timeline

10 April 2014

Primary endpoint
8 March 2016

8 March 2016

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	100
Start date	10 April 2014
Primary completion	8 March 2016
Estimated completion	8 March 2016

Drugs / interventions tested

Alternate Day Fasting
Exercise

Conditions studied

Overweight — all drugs for Overweight →
Obesity — all drugs for Obesity →
Diet Modification — all drugs for Diet Modification →
Exercise — all drugs for Exercise →

Sponsor

Gangnam Severance Hospital

Who can join

Adults 20 to 65, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alternate day fasting is known to be helpful to control weight and have a positive effect on insulin resistance and cardiovascular risk factors. However, there have been no studies on weight reduction program combining alternate day fasting with exercise which preserves lean mass in Korea. The purpose of this randomized clinical trial is to examine the effects of alternate day fasting and exercise on weight reduction, visceral fat, and metabolic parameters in overweight or obese adults.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Intermittent fasting for the prevention of cardiovascular disease.
Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, et al · · 2021 · cited 66× · PMID 33512717 · DOI 10.1002/14651858.cd013496.pub2
Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials.
Gu L, Fu R, Hong J, Ni H, et al · · 2022 · cited 38× · PMID 35586738 · DOI 10.3389/fnut.2022.871682
Effects of alternate day calorie restriction and exercise on cardio-metabolic risk factors in overweight and obese adults: an exploratory randomized controlled study.
Oh M, Kim S, An KY, Min J, et al · · 2018 · cited 37× · PMID 30219052 · DOI 10.1186/s12889-018-6009-1
Comparing caloric restriction regimens for effective weight management in adults: a systematic review and network meta-analysis.
Huang J, Li Y, Chen M, Cai Z, et al · · 2024 · cited 6× · PMID 39327619 · DOI 10.1186/s12966-024-01657-9
A Narrative Review of Intermittent Fasting With Exercise.
Gabel K, Hamm A, Czyzewski O, Sanchez Perez J, et al · · 2025 · cited 4× · PMID 38830534 · DOI 10.1016/j.jand.2024.05.015

Verify or expand the search:

Other trials of Alternate Day Fasting

Trials testing the same drug.

NCT04732130 — Monitoring During Different Intermittent Fasting Protocols in Non-Obese Adults · NA · completed
NCT03447600 — Diet-Induced Variability in Appetite (DIVA) · NA · completed

Other recruiting trials for Overweight

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03652532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 29 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing